{
    "clinical_study": {
        "@rank": "58782", 
        "arm_group": [
            {
                "arm_group_label": "Probiotics", 
                "arm_group_type": "Active Comparator", 
                "description": "Dietary supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dietary supplement"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the benefit and tolerability of a probiotic product\n      in subjects with increased susceptibility to common cold."
        }, 
        "brief_title": "Probiotics in Prevention of Common Cold", 
        "condition": "Viral Infections of the Upper Respiratory Tract", 
        "condition_browse": {
            "mesh_term": [
                "Common Cold", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  males and females\n\n          -  age 18-70 years\n\n          -  increased risk for common cold (at least 4 episodes within 12 months)\n\n          -  commitment to adhere to former diet and physical activity\n\n          -  commitment not to use any products that may influence the study outcome (e.g. immune\n             suppressants/immune stimulants, including paramedication such as e.g. Echinacea,\n             analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza\n             remedies, mouth or throat therapeutics, decongestants, antibiotics,\n             anti-histaminergic drugs, probiotics) during the study (except for rescue medication,\n             see 7.5)\n\n          -  women of child-bearing potential have to agree to use appropriate birth control\n             methods Written consent of the subject to participate is a prerequisite for study\n             participation.\n\n        Exclusion Criteria:\n\n          -  acute / chronic upper / lower airways disease\n\n          -  chronic cough of any origin\n\n          -  any allergic reaction that may influence the study outcome (e.g. acute/chronic\n             rhinitis)\n\n          -  history of nasal reconstructive surgery\n\n          -  presence of nasal ulcers or nasal polyps\n\n          -  severe nasal septum deviation or other condition that could cause nasal obstruction\n\n          -  congenital or acquired immunodeficiency disease (e.g. HIV infection)\n\n          -  Bechterew's disease\n\n          -  body temperature above 37.5\u00b0C\n\n          -  suspected swine flu or influenza\n\n          -  vaccination with a vaccine containing an adjuvant within 3 months prior to study\n             start and during the study\n\n          -  vaccination with a vaccine not containing an adjuvant within 6 weeks prior to study\n             start and during the study\n\n          -  stomach/gastrointestinal diseases\n\n          -  serious organ or systemic diseases\n\n          -  sleep disorder\n\n          -  psychiatric disorders\n\n          -  known sensitivity to the ingredients of the investigational product\n\n          -  regular intake of products that may influence the study outcome (e.g. immune\n             suppressants/immune stimulants, including paramedication such as e.g. Echinacea,\n             analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza\n             remedies, mouth or throat therapeutics, decongestants, antibiotics,\n             anti-histaminergic drugs, probiotics) within the last 4 weeks prior to study start\n\n          -  habitual usage of nasal drops/spray\n\n          -  pregnancy or nursing\n\n          -  alcohol / drug abuse\n\n          -  simultaneous participation in another clinical trial or participation in a clinical\n             trial within the last 30 days\n\n          -  insufficient compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "312", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013934", 
            "org_study_id": "PAB/011013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probiotics", 
                "intervention_name": "Probiotic", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "mschaudt@analyze-realize.com", 
                "last_name": "Marco Schaudt"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "A&R"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Benefit and Tolerability of a Probiotic Product in Subjects With Increased Susceptibility to Common Cold", 
        "overall_contact": {
            "email": "ila@probi.se", 
            "last_name": "Irini Lazou Ahr\u00e9n, PhD", 
            "phone": "+46 46 286 89 22"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Charit\u00e9 - Universit\u00e4tsmedizin Berlin Ethikkommission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Severity of cold symptoms based on the questionnaire WURSS-21 during the cold episodes throughout the study period, in comparison between verum and placebo group", 
            "measure": "Severity of cold symptoms", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013934"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of common cold episodes", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Probi AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Probi AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}